瑞普生物：报告期内公司获得4项新兽药注册证书

Core Insights - The company, Reap Bio, announced significant advancements in its research and development, including the acquisition of four new veterinary drug registration certificates and six clinical approvals, highlighting its strong position in the animal health industry [1] R&D Achievements - The company obtained four new veterinary drug registration certificates, including a new four-in-one inactivated vaccine for chickens and a bivalent yolk antibody for duck hepatitis virus [1] - Six clinical approvals were achieved, notably for the world's first mRNA vaccine for food animals targeting porcine epidemic diarrhea virus, showcasing the company's advanced mRNA vaccine development platform [1] - The company secured six authorized invention patents, reinforcing its innovative capabilities in the animal health sector [1] Product Planning - In the second half of the year, the biological products segment will focus on launching major products such as a new two-in-one live vaccine and upgraded multi-valent vaccines [1] - The pharmaceutical formulation segment plans to introduce self-developed long-acting formulations and new preparations for treating mycoplasma infections in poultry, marking a significant step in product innovation [1]